X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NG-01 is a proprietary population of autologous bone marrow-derived stem cells designed to secrete high levels of remyelinating and neurotrophic factors (NG-01) at the central nervous system site of injury. It is being evaluated for the treatment of multiple sclerosis.
Lead Product(s): NG-01
Therapeutic Area: Neurology Product Name: NG-01
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
Results published in Stem Cells Translational Medicine show significant reduction of NF-L, a biomarker for neuronal damage, in patients with progressive multiple sclerosis after treatment with NG-01 stem cells.
Lead Product(s): Mesenchymal Stem Cells
Therapeutic Area: Neurology Product Name: NG-01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hadassah Medical Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
